Miguel Tovar
1,714 Added | 1 Magazine | 1 Following | 67 Followers | @MiguelTovar3nhq | about.me/tovar
Novartis CEO feels heat on U.S. generics, Cosentyx drop
ZURICH (Reuters) - Swiss drugmaker Novartis' first quarterly results under new CEO Vas Narasimhan have been marred by a prized psoriasis treatment that disappointed and a sharp slump in sales by its U.S. generics unit.<p>The stock declined 2.2 percent at 1200 GMT, more than double the fall of the …
BiotechnologyExperts query case for GlaxoSmithKline's new 3-in-1 lung drug
LONDON (Reuters) - Two medical experts have urged caution in using a new three-in-one inhaler for chronic lung disease from GlaxoSmithKline, which the company hopes will help it keep its lead in respiratory medicine despite rising competition.<p>Trelegy Ellipta was licensed for use last year and full …
BiotechnologyChina's pharmaceutical industry is poised for major growth
China, the world's manufacturing powerhouse, is moving toward a more value-add economy and there's one major industry where the country could …
BiotechnologyP&G to buy German Merck's consumer health unit for $4.2 billion
(Reuters) - Procter & Gamble Co (P&G) has agreed to acquire Merck KGaA's consumer health unit for 3.4 billion euros ($4.2 billion), giving it vitamin brands such as Seven Seas and greater exposure to Latin American and Asian markets.<p>The maker of Pampers diapers and Gillette razors said the deal …
Procter & GambleGSK flags pharma M&A ambitions by poaching Roche deal-maker
LONDON (Reuters) - GlaxoSmithKline (GSK.L) signaled its intention to boost its drug pipeline through deals on Wednesday by hiring Kevin Sin from Roche's (ROG.S) Genentech unit to lead a worldwide search for promising experimental products.<p>He is the first senior hire by GSK's new research and …
BiotechnologyIndustry fears disruption as EU excludes UK from drug approvals
LONDON (Reuters) - A European decision to exclude Britain from the EU's drug approval system from March 30 2019 - the day after Brexit - has raised alarm among drugmakers, who fear the abrupt change could disrupt medicine supplies to patients.<p>The move confounds hopes for continued joint cooperation …
United KingdomSanofi sells European generics to Advent for $2.4bn
The deal will create a new, independent European generics company
BiotechnologyBristol Partners With Illumina On Diagnostic Test To Use With Opdivo
Drug giant Bristol-Myers Squibb is partnering with Illumina, the leading maker of DNA sequencing gear, to develop diagnostic tests that will pair with Bristol’s cancer drugs.<p>One of the first tests will be for tumor mutation burden, a measure of how much a tumor’s DNA has changed compared to the …
BiotechnologyNovartis CEO: How To Create Cheaper Alternatives To The Most Expensive Drugs
Recently, FDA Commissioner Scott Gottlieb addressed those in attendance at America’s Health Insurance Plans’ (AHIP) National Health Policy Conference. His comments created a lot of visibility around several critical topics, including patient access to innovative treatments, cost-effectiveness, and …
PharmaPfizer's Deal Potential Doesn't Stop at Bristol-Myers
Biopharma investors have enjoyed a recent streak of small-to-medium sized M&A, but they really hunger for something bigger. Pfizer Inc. is considered …
BiotechnologyNovartis bets big on gene therapy with $8.7 billion AveXis deal
ZURICH (Reuters) - Swiss drugmaker Novartis (NOVN.S) is moving further into gene therapy by buying AveXis (AVXS.O) for $8.7 billion, adding a rare-disease treatment that could reap billions in sales.<p>The acquisition reflects a surge of interest in biotech deal-making as large pharmaceutical …
BiotechnologyPfizer in talks with P&G on sale of its consumer business, though they are far apart on price: Sources
Pfizer is in talks with Procter & Gamble on a sale of its consumer business, sources tell CNBC.<p>The business includes Chapstick lip balm, Advil pain …
Procter & GambleAI. Telemedicine. Quantum. New Novartis Boss Says Tech Will Finally Change The Drug Biz
What does the youngest chief executive in Big Pharma want? A control room straight off the starship Enterprise.<p>When Vas Narasimhan, 41, took the helm of drug giant Novartis in February, he’d already put the project in motion. Novartis scouts were dispatched to visit air traffic control towers and …
BiotechnologyGSK pulls out of $20 billion race for Pfizer consumer assets
LONDON (Reuters) - GlaxoSmithKline (GSK.L) has quit the race to buy Pfizer's (PFE.N) consumer healthcare business, endangering an auction the U.S. drugmaker hoped would bring in as much as $20 billion.<p>It was not immediately clear whether there were other offers for the business, which includes …
BiotechnologyA $158 Billion Drug Giant Faces an Identity Crisis
Blockbuster arthritis treatment Humira helped build AbbVie Inc. into a pharmaceutical-industry behemoth. Now investors are growing concerned about …
BiotechnologyNovartis touts U.S. filing plans for MS drug as patent losses loom | Reuters
ZURICH (Reuters) - Novartis plans to file its BAF312 multiple sclerosis drug for U.S. approval within weeks, the Swiss drugmaker said on Friday, as it seeks to refresh its portfolio of neurological medicines that is about to be hit by patent losses.<p>The logo of Swiss drugmaker Novartis is seen …
NovartisGlaxoSmithKline in pole position for $20bn Pfizer unit
GlaxoSmithKline is in pole position to win the race for the consumer healthcare business of US pharma giant Pfizer, after it beat a rival bid from …
PfizerNovo Nordisk’s semaglutide obesity trial hits the mark
The injection helped adults lose up to 13.8% of their body weight in a year
BiotechnologyPatients regain sight with stem cell treatment in U.K. clinical trial
Nearly three years ago, 86-year-old Douglas Waters developed severe vision problems. He was diagnosed with severe wet age-related macular …
University College LondonLundbeck signs $1.1bn deal for Prexton and Parkinson’s drug
Foliglurax is currently in phase II testing for LID, muscle stiffness and ‘freezing’
BiotechnologyChina pharma boosts generics exports to US
Chinese pharmaceutical companies are stepping up their push into the US generic drugs market with the number of approvals for copycat medicines …
Generic DrugsTheranos and the Problem With Booming Biotech Funding
Theranos has been a big embarrassment for the world of private health-care investment. It deepened on Wednesday, when the SEC detailed what it called …
BiotechnologyRoche CEO says new drugs will offset biosimilar incursions
ZURICH (Reuters) - Swiss drugmaker Roche will be able to compensate or overcompensate for falling revenue from patent-expired drugs facing competition from rivals' copies through its new medicines, Chief Executive Severin Schwan said on Tuesday.<p>Schwan's outlook, delivered to shareholders at the …
BiotechnologyAstraZeneca Delays Final Results of Failed Lung-Cancer Trial
AstraZeneca Plc delayed the final results from its Mystic lung-cancer trial, which failed last year, to collect more data on how long patients live …
CancerIn The War Against High Drug Prices, Some Patients Are Collateral Damage
Tommy Mann’s dad had his first heart attack when he was 29. That’s how he found out that he had a genetic disorder, familial hypercholesterolemia (FH), that causes very high cholesterol levels. Tommy and his two sisters have FH, too. Even on the top dose of cholesterol pills, Tommy Mann’s …
PharmaBiogen to buy Pfizer's neurology drug in deal nearing $600 mln
March 12 (Reuters) - Biogen Inc said on Monday it would buy Pfizer Inc’s experimental treatment for cognitive impairment associated with schizophrenia in a deal whose value could near $600 million.<p>Biogen said it would pay Pfizer $75 million upfront, up to $515 million in development and …
BiotechnologyNovartis CEO: We Need a Different Approach to Drug Discovery
Heart disease remains the number one cause of death worldwide, accounting for more than 30% of all global deaths. Yet the discovery of new …
Digital HealthFDA's Gottlieb blames industry 'Kabuki drug pricing' for high costs
WASHINGTON (Reuters) - U.S. Food and Drug Administration chief, Scott Gottlieb, criticized pharmacy benefit managers, health insurers and drugmakers on Wednesday for "Kabuki drug-pricing constructs" that profit the industry at the expense of consumers.<p>The comments, made at a conference organized by …
FDANovartis pushes ‘virtual’ clinical trial concept
<b>Running clinical trials is an expensive business and Novartis has signed a new deal with US tech company Science 37 to try to take some of the costs</b> …